Skip to content

Covid-19 vaccine accounts for 41% of Pfizer’s $19 billion Q2 revenue

Covid-19 vaccine accounts for 41% of Pfizer's $19 billion Q2 revenue

United States pharmaceutical giant Pfizer (NYSE: PFE) has announced a record revenue during Q2 2021, reflecting the gains from rolling out the coronavirus vaccine. 

The company reported a net profit of $5.56 billion with revenues of $18.98 billion for the second quarter. The vaccines scientifically identified as BNT162b2 contributed a share of 41% of the company’s revenue. 

Notably, between 2016 and 2020, Pfizer’s revenue remained relatively flat, growing by 8.2%. 

The growth in revenue during the quarter comes after Pfizer signed more deals to supply the vaccine to other countries. The revenue will surge further, considering that the company expects to deliver 2.1 billion doses of the mRNA vaccine this year. Therefore, Pfizer will raise its revenue guidance to $33.5 billion from $26 billion. 

Pfizer revenue. Source:

The distribution will then expand the company’s revenue guidance to between $78 to $80 billion or an 86- 91% year-over-year growth. 

 “The second quarter was remarkable in a number of ways. Most visibly, the speed and efficiency of our efforts with BioNTech to help vaccinate the world against COVID-19 have been unprecedented, with now more than a billion doses of BNT162b2 having been delivered globally,” Pfizer CEO Albert Bourla said. 

Pfizer revenue projected to soar further

The company’s prospects appear bright, considering there are plans for a booster vaccine authorization. In early July, the company, alongside BioNTech, indicated that it witnessed signs of waning immunity induced by its Covid vaccines.

As the world continues to handle the deal with the delta variant, the two companies are working on a shot to handle the strand.

Compared to other drug manufacturers, Pfizer stood a better chance of recording massive revenue since the company was the first to emerge with the Covid-19. Furthermore, the revenue will remain sizable even if it splits its profits with the vaccine manufacturing partner, BioNTech.


Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in 70+ cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users
eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk. eToro USA LLC does not offer CFDs, only real Crypto assets available. Don’t invest unless you’re prepared to lose all the money you invest.

Read Next:

Weekly Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Disclaimer: The information on this website is for general informational and educational purposes only and does not constitute financial, legal, tax, or investment advice. This site does not make any financial promotions, and all content is strictly informational. By using this site, you agree to our full disclaimer and terms of use. For more information, please read our complete Global Disclaimer.